Genmab tops red C25 after study data. Oct. 5, 2026 at 11:56 MarketWire Genmab took the top spot in the Danish elite index on Monday after positive trial data for a new drug candidate, while upward revisions are helping send ChemoMetec and Alm. Brand higher among the small-cap stocks. - It is a market without any major swings compared to Friday. Not much has happened over the weekend, so the things that were in focus... Written for companies. By those who know them Finans Quarterly Subscription for one user Unlimited access for 3 months Annual price: DKK 5,180 Finans Annual Subscription for one user Save DKK 680 Unlimited access for 12 months Annual price: DKK 4,500 Finans Business Subscription for multiple users Finans Business is for companies that want a tailor-made solution with multiple accesses combined in a single subscription. Payment options Try Finans for 30 days - and get access to all content. Order access

Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.

Genmab reported first-half 2026 revenue of $2.05 billion, up 25% year-on-year from $1.64 billion, though shares fell 2.6% following the announcement. The Danish biotechnology company's growth was driven by higher DARZALEX and Kesimpta royalties and increased EPKINLY net product sales. Royalty revenue reached $1.71 billion, up 24% from $1.38 billion. Global net sales of EPKINLY/TEPKINLY surged 48% to $312 million from $211 million. Adjusted operating profit increased to $656 million from $554 million in the prior-year period. Genmab raised its full-year 2026 revenue guidance to a range of $4.33 billion to $4.53 billion, up from the previous range of $4.07 billion to $4.40 billion.